Low testosterone is a documented cause of chronic fatigue in men with confirmed hypogonadism. Learn what the evidence actually supports, what remains uncertain, and how to get properly diagnosed before considering TRT.
Learn how TRT addresses muscle loss from low testosterone, what the clinical trials show on lean mass gains, who qualifies, and how to start treatment safely.
Evidence-based guide to testosterone replacement therapy (TRT) for osteoporosis in men with hypogonadism. Covers bone density data, dosing, monitoring, and how TRT compares with bisphosphonates.
A board-reviewed guide to testosterone replacement therapy for transgender men, covering dosing, timelines, monitoring, fertility, and age-specific considerations from under-30 to over-65.
A guide to testosterone replacement therapy for men over 50, covering eligibility, dosing protocols, cardiovascular safety, bone health, and how TRT differs across age groups including men over 65.
A comparison of testosterone replacement therapy (TRT) vs clomiphene (Clomid) and enclomiphene for low testosterone, covering efficacy, fertility, side effects, and how to choose between cypionate, enanthate, and gel formulations.
A guide to combining TRT with GLP-1 receptor agonists like semaglutide or tirzepatide. Covers dosing, timing, who qualifies, monitoring, and what the clinical evidence actually supports and does not yet support for men at different ages.
A practical, clinician-backed guide to reading health research studies without getting lost in statistics, p-values, or industry spin. Learn exactly how to evaluate a trial, guideline, or meta-analysis before making any health decision.
Evidence-based metformin dosing for adults aged 30 to 49, covering starting doses, titration schedules, maximum doses, renal thresholds, and real-world considerations for working-age patients with type 2 diabetes or prediabetes.
A clinical and coverage guide to Aetna (CVS Health) metformin coverage, prior authorization criteria, formulary tiers, step therapy requirements, and appeal pathways for type 2 diabetes and prediabetes.
A complete guide to Blue Cross Blue Shield (Federated) coverage for metformin, including formulary tiers, prior authorization, step therapy, appeals, and out-of-pocket cost options.
Metformin food effects differ between IR and XR. Review alcohol, B12, calcium and supplement questions with formulation-specific evidence and study limits.
A guide to using metformin for metabolic syndrome: what the trial data shows, how to dose it, who qualifies, and what side effects to watch for.
A state-by-state guide to Medicaid coverage of metformin for type 2 diabetes and prediabetes, including formulary tiers, prior authorization criteria, step therapy rules, and how to appeal a denial.
A complete guide to Medicare Advantage metformin coverage, formulary tiers, prior authorization, step therapy, and how to appeal a denial, with clinical context.
A clinician-level review of metformin pharmacogenomics, covering SLC22A1, SLC47A1, ATM, and other variants that explain why response to metformin differs so dramatically between patients.
Metformin eGFR rules from the label: contraindicated below 30, starting not recommended at 30 to 45, and benefit-risk review if eGFR falls below 45.
Everything a young adult (18-29) needs to know about metformin monitoring: which labs to check, how often, warning signs, fertility considerations, and how to stay safe long-term.
A comparison of compounded methimazole versus branded Tapazole covering bioavailability, cost, dosing, safety, and when each formulation is appropriate for hyperthyroidism and Graves disease management.
A clinical guide to monitoring MK-677 (ibutamoren) use in adults aged 30 to 49: which labs to order, how often, what thresholds matter, and what side effects to watch for.
A breakdown of MK-677 (ibutamoren) safety data for adults ages 30 to 49, covering adverse effects, IGF-1 risks, insulin resistance, and how to weigh the limited evidence before considering use.
A synthesis of MK-677 (ibutamoren) real-world evidence, mechanism of action, clinical trial data, and safety signals. Includes inline PubMed citations throughout.
A clinical review of MOTS-c mitochondrial peptide and its impact on cognitive function, covering mechanisms, animal data, emerging human research, and what patients considering this peptide should know.
A guide to discontinuing MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) safely, covering mechanism, tapering rationale, metabolic rebound risk, and what the evidence actually shows.
A clinician-level review of what happens when you stop MOTS-c peptide therapy, whether rebound metabolic effects are real, what the mitochondrial biology predicts, and how to discontinue safely based on current research.
A physician-level review of MOTS-c mitochondrial peptide use in transplant recipients, people living with HIV, older adults, and other special populations. Covers mechanism, dosing, safety signals, and current evidence.
A clinician-level review of tirzepatide (Mounjaro) use in patients with autoimmune conditions, covering immunomodulatory mechanisms, disease-specific risks, monitoring protocols, and the latest trial evidence.
Does Mounjaro (tirzepatide) improve or impair cognitive function? A clinician-level review of the trial data, proposed mechanisms, and what patients with type 2 diabetes or obesity can realistically expect.
A guide to using tirzepatide (Mounjaro) for menopause-related weight gain, covering clinical trial data, dosing protocols, HRT combinations, and realistic outcomes.
A guide to using tirzepatide (Mounjaro) for obesity with BMI ≥30, covering SURMOUNT trial data, weekly dosing schedules, side-effect management, and insurance realities.
A guide to using tirzepatide (Mounjaro) for PCOS: trial evidence, dosing schedules, hormonal effects, insulin resistance benefits, and how to talk to your provider about off-label use.
Tirzepatide (Mounjaro) is used off-label for prediabetes in high-risk patients. Review the clinical trial data, dosing schedules, side-effect profile, and insurance realities before starting treatment.
A guide to tirzepatide-related hair loss, skin changes, and nail effects. Covers the science behind GLP-1/GIP-driven telogen effluvium, clinical evidence, and what patients can do.
A deep dive into how tirzepatide (Mounjaro) alters resting metabolic rate, fat oxidation, thermogenesis, and energy expenditure, with primary-literature citations and real dosing data.
Complete clinical guide to the Mounjaro (tirzepatide) missed-dose protocol, including timing rules, what to skip, pharmacokinetic reasoning, and how tirzepatide's dual GIP/GLP-1 mechanism shapes dosing decisions.
A complete guide to the Mounjaro (tirzepatide) monitoring schedule, covering baseline labs, follow-up bloodwork, vital signs, and exam intervals backed by FDA labeling, ADA guidelines, and primary clinical trials.
Step-by-step clinical protocol for restarting Mounjaro (tirzepatide) after acute illness, including dose step-down rules, hydration checks, GI monitoring, and evidence from SURPASS trials.
A guide to switching between tirzepatide (Mounjaro) and other GLP-1 or dual GIP/GLP-1 medications, including semaglutide, dulaglutide, and liraglutide. Covers mechanism, dose conversion, washout timing, and clinical evidence.
NMN and NR are dietary supplements, not FDA-approved drugs. This page has no Aetna policy, so check your plan documents or ask Aetna about coverage.
No validated taper or stopping protocol exists for NMN or NR. This page covers what trials reported during dosing and what the evidence shows.
A guide to NMN and NR overdose risk, toxicology, mechanism of action, and management steps when someone takes too much nicotinamide mononucleotide or nicotinamide riboside.
Reviews human trial evidence, doses studied, safety data and US regulatory status for NMN and NR, noting no trials in post-bariatric patients.
An evidence-based guide to NMN and NR supplement safety during pregnancy and breastfeeding, covering mechanism, human trial data, animal studies, and clinical recommendations.
Human trial safety data for NMN and NR, plus FDA's 2022 position on NMN and its 2025 reversal, and what is still unknown about long-term use.
A guide to NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) injection technique, pharmacology, dosing, and the clinical trial data behind NAD+ precursor therapy.
Enclomiphene has no FDA approval for any use, and EMA refused it in 2018. In two phase 3 trials, 78.8% and 81.3% of men reached normal testosterone.
A guide to using copper tripeptide GHK-Cu for hair growth off-label, covering the evidence base, dosing protocols, and monitoring requirements.
Is metformin a longevity drug? We review the biology, clinical trial data from TAME and beyond, GRADE evidence levels, off-label status, and what prescribers and patients need to know before considering metformin for aging.
Metformin is FDA-approved for type 2 diabetes but is used off-label for weight maintenance. Learn what the clinical evidence shows, who may benefit, and how dosing is typically structured.
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, but physicians prescribe it off-label for weight loss. Learn what the SURMOUNT trials showed, how dosing works, and what to expect.
Ozempic kidney protection: the approved use in type 2 diabetes and CKD, FLOW trial results, weekly dosing, monitoring and evidence beyond diabetes.
A deep dive into using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for polycystic ovary syndrome. Covers the clinical evidence, GRADE ratings, FDA approval context, dosing, risks, and when to consider Wegovy or metformin instead.
A clinical evidence summary of liraglutide 3 mg (Saxenda) used off-label for nonalcoholic steatohepatitis (NASH), covering trial data, mechanisms, dosing, and guideline positions.
A clinical evidence summary of semaglutide 2.4 mg (Wegovy) for cardiovascular prevention, covering SELECT trial data, FDA-approved indications, off-label context, and GRADE-level evidence ratings.
Zepbound (tirzepatide) is FDA-approved for obesity, not diabetes, that role belongs to Mounjaro. Here is what the clinical trial data show, how physicians approach off-label prescribing, and what patients should know before starting.
Zepbound (tirzepatide) is FDA-approved for obesity, not diabetes. This evidence summary covers the clinical trial data, off-label prescribing rationale, and how it compares to Mounjaro for blood-sugar control.
A clinical and insurance guide explaining Blue Cross Blue Shield Federated coverage, prior authorization, formulary tier, step therapy, and appeal strategies for oral micronized progesterone (Prometrium).
A clinician-level review of how oral micronized progesterone (Prometrium) affects cognitive function, memory, mood, and neuroprotection, with primary-literature citations and dosing guidance.
50 mg is not a Prometrium dose. The label's endometrial-protection regimen is 200 mg at bedtime for 12 days per 28-day cycle with conjugated estrogens.
What to check after missing oral micronized progesterone, why Prometrium, Utrogestan, and combined capsules cannot share one cutoff, and which regimen details matter.